Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,516 across all filing types
Latest filing 2025-02-10 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR ENYITAN (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL
Regulatory Filings Classification · 88% confidence The document is a voluntary corporate announcement on HKEx regarding the marketing approval of a new drug indication. It does not present financial results, voting information, share issuances, or management changes. It is not a periodic report or investor presentation but a general regulatory-type announcement. Therefore, it falls under the general regulatory announcement category (RNS).
2025-02-10 English
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 78% confidence The document is a voluntary announcement on the Hong Kong Exchange about FDA approval to conduct clinical trials for a drug. It is not an annual or interim report, earnings release, board change, dividends notice, share transaction, M&A update, or any other specific category. It does not include a report attachment or filing itself but is a general business/regulatory announcement. Therefore it falls into the fallback category ‘Regulatory Filings’ (RNS).
2025-02-10 English
VOLUNTARY ANNOUNCEMENT - SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 75% confidence The document is a voluntary announcement regarding clinical trial approval for the company’s vaccine candidate, published on the Hong Kong Exchange with standard disclaimer language. It is not a financial report, earnings release, dividend notice, board change, or any of the specific categories listed. It does not present financial data or results, nor is it soliciting votes or describing M&A or share transactions. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2025-02-07 English
CHANGE OF SHARE REGISTRAR
Regulatory Filings Classification · 85% confidence The document is a brief company announcement informing shareholders of an administrative change (the change of the share registrar) and does not provide financial results, proxy materials, dividends, or legal proceedings. It is a routine regulatory announcement falling into the generic Regulatory Filings category.
2025-02-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025
Regulatory Filings Classification · 60% confidence The document is a monthly return (Form FF301) submitted to the Hong Kong Exchange under Listing Rule 19B detailing movements in issued and treasury shares, share options, repurchases, etc. It is a regulatory compliance filing rather than an earnings release, capital raise, management change, or financial report. It does not announce or attach a separate report; it is the actual submission form. This falls under general regulatory filings that do not fit other specific categories.
2025-02-03 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 93% confidence The document is a Next Day Disclosure Return (Form FF305) filed by a Hong Kong–listed issuer (CSPC Pharmaceutical Group Limited) pursuant to Main Board Rule 13.25A/GEM Rule 17.27A, detailing the company’s share repurchases and cancellations. It is clearly a report of the company buying back its own shares. This aligns with the “Transaction in Own Shares” category. Thus, the correct filing code is POS.
2025-01-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.